New hope for PAH patients in international drug trial
NCT ID NCT00993408
Summary
This study tested an experimental oral medication called ACT-293987 for adults with pulmonary arterial hypertension (PAH), a serious lung and heart condition. Participants received either the drug or a placebo twice daily for 21 weeks to see if it improved blood flow in their lungs and walking ability. The goal was to determine if this medication could help control the disease alongside existing treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Respiratory Medicine, Hannover Medical School
Hanover, 30625, Germany
-
Gasthuisberg University Hospital, Pneumology
Leuven, 3000, Belgium
-
Hammersmith Hospital
London, W12 0HS, United Kingdom
-
Hopital Antoine Beclere, Pneumologie
Paris, France
-
Hospital Sant'Orsola Malpighi, Cardiology's Department
Bologna, 40138, Italy
-
Instytut Gruzilcy i Chorob Pluc, Klinika Chorob Wewnetrznych Klatki Piersiowej
Warsaw, 01-138, Poland
-
Medizinische Universitat Wien, Universitatsklinik fur Innere Medizin II, Kardiologie
Vienna, 1090, Austria
-
Semmelweis University, Clinic of Pulmonology
Budapest, H-1125, Hungary
Conditions
Explore the condition pages connected to this study.